POMDOCTOR LIMITED Enhances Internet Hospital Growth via Strategic Pharma Partnerships

POMDOCTOR LIMITED to Drive Internet Hospital Expansion with Pharma Collaborations

Guangzhou, China - January 16, 2026
POMDOCTOR LIMITED, listed on NASDAQ as POM, is a prominent online medical service provider in China specializing in chronic disease management. Recently, the company disclosed its advancements in business collaborations with top-tier domestic pharmaceutical firms. These strategic alliances are expected to play a crucial role in augmenting POMDOCTOR's internet hospital model while enhancing profitability over the long term.

China's rapidly aging population and shifting demographics have catalyzed substantial growth in the online healthcare sector, particularly its internet hospitals and online pharmaceuticals. According to recent findings from Yaozh.com, online pharmaceutical sales in China surged from approximately RMB 19 billion in 2020 to an estimated RMB 71.8 billion (nearly USD 10.3 billion) by 2024, showing a remarkable compound annual growth rate (CAGR) of 39.4%.

In light of these profitable market trends, POMDOCTOR is stepping up its collaborative efforts with pharmaceutical companies to harness emerging opportunities. The company has engaged in multiple sales and purchase agreements with well-known industry players and innovative drug manufacturers, including Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical, and Eddingpharm (Suzhou).

These strategic partnerships facilitate the introduction of innovative and patented pharmaceutical products on POMDOCTOR's internet hospital platforms, thereby increasing access to cutting-edge treatment alternatives for both medical professionals and patients. Additionally, these collaborations offer pharmaceutical manufacturers new, efficient sales channels through internet hospitals, enhancing their market reach.

Through the established agreements, POMDOCTOR stands to gain various incentives, including special discounts, rebates, and sales bonuses, contingent upon meeting predetermined sales targets. In a statement, Mr. Zhenyang Shi, Chairman and CEO of POMDOCTOR, emphasized the transformative potential of the online pharmaceutical sales landscape, stating, "The rapidly expanding market in China not only affords significant growth opportunities for pharmaceutical manufacturers seeking efficient distribution channels, but also advantages for healthcare platforms. By establishing adaptable collaboration models, we foster mutually beneficial outcomes, integrating the strengths of all parties involved."

Mr. Shi elaborated on the mutual benefits of this strategic approach, illustrating how it enhances channel oversight for pharmaceutical firms, diminishing reliance on conventional large distributors, thereby facilitating more targeted marketing strategies and improved cash flow management. In turn, online medical platforms gain consistent and direct access to top-tier manufacturers, ensuring product quality while enhancing their competitive edge in the market. Furthermore, customers like pharmacies and patients enjoy more competitive pricing, broader product choices, and increased supply stability.

As POMDOCTOR looks to the future, Mr. Shi asserts, "Our strategic development model is poised to simplify and streamline pharmaceutical distribution. This system enhances transparency, accessibility, and efficiency, reflecting the ongoing evolution of the healthcare market in China. We aim to transcend the traditional buyer-seller dynamic, establishing deeper partnerships that promote data sharing, collaborative processes, and long-term value creation."

About POMDOCTOR LIMITED

As one of the leading online medical service platforms for chronic diseases, POMDOCTOR LIMITED ranks sixth in China's internet hospital sector based on the volume of contracted physicians, according to market analysis by Frost & Sullivan. The company focuses on integrating chronic disease management with pharmaceutical services, creating a cohesive service model that connects patients with healthcare providers and pharmacies. Through continuous improvement in its service efficacy, POMDOCTOR aims to address patients' healthcare needs, aspiring to become a premier trusted platform in the field. For more information, please visit POMDOCTOR's official site.

Forward-Looking Statements

Some statements within this announcement comprise forward-looking remarks that involve several risks and uncertainties. They hinge on the company's current anticipations and projections concerning future events impacting its financial health, operations, strategic objectives, and financing needs. Investors might identify these statements through keywords such as "estimates," "anticipates," and so forth. While POMDOCTOR maintains a forward-looking perspective, the company does not guarantee that such expectations will be met, suggesting that actual results may vary significantly from the projected outcomes. Investors are encouraged to monitor additional factors affecting future performance in the company's filings with the SEC.